Key Points
- Director Eric Sachetta bought 9,708 Sensus Healthcare shares for $31,939 at an average price of $3.29, increasing his direct holdings by 4.64% to 219,018 shares. He also purchased 45,622 additional shares in two other August transactions.
- Sensus Healthcare reported a significant quarterly miss, posting an adjusted loss of $0.53 per share versus the expected $0.12 loss and revenue of $2.29 million compared with $4.60 million expected.
- SRTS shares opened at $3.52, up 4.5%, while analyst sentiment remained a “Moderate Buy” with a consensus price target of $5.83; institutional investors own 25.3% of the company.
Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) Director Eric Sachetta purchased 9,708 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The stock was bought at an average cost of $3.29 per share, for a total transaction of $31,939.32. Following the completion of the acquisition, the director directly owned 219,018 shares in the company, valued at $720,569.22. The trade was a 4.64% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Eric Sachetta also recently made the following trade(s):
- On Thursday, August 27th, Eric Sachetta acquired 10,925 shares of Sensus Healthcare stock. The shares were bought at an average price of $3.18 per share, with a total value of $34,741.50.
- On Monday, August 24th, Eric Sachetta purchased 34,697 shares of Sensus Healthcare stock. The shares were bought at an average price of $3.25 per share, with a total value of $112,765.25.
Sensus Healthcare Trading Up 4.5%
Shares of NASDAQ SRTS opened at $3.52 on Friday. The stock has a fifty day simple moving average of $3.05 and a two-hundred day simple moving average of $3.52. Sensus Healthcare, Inc. has a 1-year low of $2.66 and a 1-year high of $5.49. The firm has a market cap of $57.94 million, a price-to-earnings ratio of -3.74 and a beta of 1.10.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.41). The firm had revenue of $2.29 million during the quarter, compared to analysts' expectations of $4.60 million. Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in SRTS. Geode Capital Management LLC grew its position in Sensus Healthcare by 2.5% during the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company's stock worth $730,000 after buying an additional 3,766 shares in the last quarter. Sachetta LLC raised its holdings in shares of Sensus Healthcare by 6.8% in the 4th quarter. Sachetta LLC now owns 148,508 shares of the company's stock valued at $591,000 after acquiring an additional 9,500 shares in the last quarter. Pacific Ridge Capital Partners LLC raised its holdings in shares of Sensus Healthcare by 21.8% in the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company's stock valued at $2,781,000 after acquiring an additional 125,245 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Sensus Healthcare during the 4th quarter valued at about $79,000. Finally, State Street Corp grew its holdings in shares of Sensus Healthcare by 5.2% during the fourth quarter. State Street Corp now owns 69,252 shares of the company's stock worth $276,000 after purchasing an additional 3,400 shares in the last quarter. Institutional investors own 25.30% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have issued reports on SRTS. Weiss Ratings downgraded Sensus Healthcare from a "sell (d)" rating to a "sell (d-)" rating in a research report on Tuesday, August 18th. Alliance Global Partners reiterated a "buy" rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Wall Street Zen lowered Sensus Healthcare from a "sell" rating to a "strong sell" rating in a research note on Saturday, May 9th. Citigroup reissued a "buy" rating on shares of Sensus Healthcare in a report on Friday, May 8th. Finally, Lake Street Capital cut their target price on Sensus Healthcare from $4.50 to $4.00 and set a "buy" rating for the company in a research note on Friday, August 14th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Sensus Healthcare presently has an average rating of "Moderate Buy" and a consensus price target of $5.83.
Get Our Latest Stock Report on SRTS
About Sensus Healthcare
(
Get Free Report)
Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.
The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
